Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RINOMAX: Rituximab in New Onset Myasthenia Gravis
2015-005749-30Phase 3Completed
- Sponsor
- Karolinska Institutet
- Start
- Apr 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myasthenia gravis (MG) comparing Rituximab (MabThera) with Placebo (2 arms). Primary endpoint: Minimal clinical MG symptoms with low-dose prednisone at 16 weeks. Started Apr 2016; status: completed.
02
Drugs
rituximab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2015-005749-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005749-30.